FDA Follows the Jab Money

FDA Follows the Jab Money

Multiple members of the FDA Committee that recommended approval of Pfizer’s COVID jab for young kids last week featured have significant connections to the pharmaceutical giant. Some of the committee members had professional and financial ties to Pfizer, having worked on projects sponsored by the drug company in the past.

Committee member Archana Chatterjee worked on a project researching the vaccination of infants for two years that was sponsored by Pfizer. Dr. Myron Levine mentored the senior director of vaccine research and development at Pfizer, Raphael Simon.

Dr. Geeta Krishna Swamy has served as a “co-investigator” for a Pfizer vaccine trial, according to Duke University. Former vice president for Pfizer Vaccines, Greg Sylvester, also had a hand in the committee.

At the meeting, 17 members voted in favor of approval, one abstained, and nobody voted against it, judging that the benefits of jabbing children between 5 and 11 years old with the Pfizer shot outweigh any other health risks. The abortion-tainted jab has not been officially approved yet, but the FDA will make a final decision within days and is expected to follow the advice of the committee.

Some experts have raised concerns over the lack of safety and efficacy data presented by Pfizer for use of its COVID vaccine in younger children. Those who have objected to a wide-scale child jab initiative have pointed to increasing safety signals based on reports to the Vaccine Adverse Event Reporting System (VAERS).

Significant risks of myocarditis have been brought to light by experts who study the available data of adverse reactions reported after children are jabbed. American cardiologist, Dr. Peter McCullough has warned about the risks of heart inflammation in children who are jabbed. In August he said: “We are at 5,093 cases of myocarditis as of August 20 in the US. We haven’t really ramped up vaccinating kids yet. This is the tip of the iceberg. In no way should a parent think that myocarditis is rare, because it’s not. We’re talking about thousands of children already have developed myocarditis.”

Pfizer admitted in a report released on Friday before the meeting that its test group was “too small to detect any potential risks of myocarditis associated with vaccination.” The pharma giant intimated that it doesn’t know the long-term effects of the jab, but studies will be conducted over the next few years.